Autres langues Citius Pharmaceuticals, Inc.

Actions

CTXR

US17322U2078

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
0,6095 ^USD	-3,51 %		-12,62 %	-19,43 %

21/05	Citius Pharmaceuticals, Inc. atteint les objectifs primaires et secondaires de l'essai de phase 3 de la solution de verrouillage antibiotique Mino-Lok	CI
14/05	Citius Pharmaceuticals, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	29/05
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	21/05
Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	21/05
Citius Pharmaceuticals : CTXR Factsheet	15/05
Citius Pharmaceuticals : CTXR Corporate Presentation	15/05
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update	14/05
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	14/05
Citius Pharmaceuticals to Participate In Upcoming EF Hutton and H.C. Wainwright Investor Conferences	13/05
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences	10/05
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering	30/04
Citius Pharmaceuticals Launches $15 Million Offering	26/04
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering	26/04
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11/04
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11/04
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference	04/04
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	18/03
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	18/03
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program	07/03
Citius Pharmaceuticals to Participate In Upcoming BIO CEO and Sidoti Investor Conferences	26/02
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Citius Pharmaceuticals, Inc.

Actions

CTXR

US17322U2078

Autres langues

Filtres